Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 13/20 | 0.53 |
| ▸ | BTK | Q06187 | 7/20 | 0.53 |
| ▸ | JAK3 | P52333 | 4/20 | 0.53 |
| ▸ | ITK | Q08881 | 6/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20216223 | 0.79 | EGFR (0.61) | CDK2CDK4SYKEGFRBTK | |
| SCHEMBL12518620 | 0.77 | EGFR (0.65) | CDK2CDK4SYKEGFRBTK | |
| SCHEMBL10187818 | 0.76 | AURKA (0.71) | CDK2CDK4SYKEGFRBTK | |
| SCHEMBL12518614 | 0.75 | EGFR (0.71) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL13166126 | 0.75 | SYK (0.67) | CDK2SYKEGFRBTKJAK3 | |
| SCHEMBL12519548 | 0.75 | SYK (0.67) | CDK2SYKEGFRBTKJAK3 | |
| SCHEMBL12518611 | 0.73 | EGFR (0.76) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL12518406 | 0.73 | JAK1 (0.69) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL15391256 | 0.73 | MAPK8 (0.60) | CDK2CDK4SYKEGFRBTK | |
| SCHEMBL12749854 | 0.72 | SYK (0.63) | CDK2CDK4SYKEGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | CDK2 32/4885CDK4 50/4885SYK 494/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CDK2 1007/4885CDK4 1995/4885SYK 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.